EP1299093A2 - Kombinationen aus bisphosphonaten, östrogenmitteln und gegebenenfalls östrogenen - Google Patents

Kombinationen aus bisphosphonaten, östrogenmitteln und gegebenenfalls östrogenen

Info

Publication number
EP1299093A2
EP1299093A2 EP01952365A EP01952365A EP1299093A2 EP 1299093 A2 EP1299093 A2 EP 1299093A2 EP 01952365 A EP01952365 A EP 01952365A EP 01952365 A EP01952365 A EP 01952365A EP 1299093 A2 EP1299093 A2 EP 1299093A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
phenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01952365A
Other languages
English (en)
French (fr)
Inventor
Simon Nicholas Jenkins
Barry Samuel Komm
Christopher Paul Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1299093A2 publication Critical patent/EP1299093A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • estrogenic agents including the treatment of bone loss, cardiovascular disease, maladies associated with or resulting from the proliferation or abnormal development of endometrial or endometrial-like tissues, and disease states or syndromes associated with estrogen deficiency.
  • This invention comprises methods of treating, preventing, alleviating or inhibiting bone disorders, including osteoporosis or Paget's disease in a mammal, preferably in a human, the methods comprising administering to a mammal in need thereof a pharmaceutically effective combination of:
  • a pharmaceutically effective amount of a bisphosphonate compound such as, but not limited to, Alendronate, Risedronate, Tiludronate, Ibandronate,
  • R x is selected from H, OH or the C1- 2 esters (straight chain or branched) or C,-C 12 (straight chain or branched or cyclic) alkyl ethers thereof, benzyloxy, or halogens; or C C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether.
  • R 2 , R 3 , R 5 , and R 6 are independently selected from H, OH or the -C12 esters
  • R 4 is selected from H, OH or the C1-C12 esters (straight chain or branched) or C,-C 12 alkyl ethers (straight chain or branched or cyclic) thereof, benzyloxy, halogens, or C,-C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, Ci-C ⁇ alkyl (straight chain or branched), or trifluoromethyl;
  • X is selected from H, C ⁇ -C6 alkyl, cyano, nitro, trifluoromethyl, halogen; n is 1, 2 or 3; Y is selected from: a) the moiety:
  • R 7 and Rs are independently selected from the group of H, C 1 -C6 alkyl, or phenyl optionally substituted by CN, C1-C6 alkyl (straight chain or branched), Ci-C ⁇ alkoxy (straight chain or branched), halogen, -OH, -CF 3 , or -OCF 3 ; or R 7 and R 8 are combined by -(CH 2 )p-, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydroxyl, halo, C ⁇ -C4alkyl, trihalomethyl, C ⁇ -C4alkoxy, trihalomethoxy, Ci-
  • a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C ⁇ _C4 alkyl)-, -N , and -S(O) m -, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C -C4alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, Ci-G-tacyloxy, C ⁇ -C4alkylthio,
  • a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C ⁇ _C4 alkyl)-, -N , and -S(O) m -, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C]-C4alkyl, trihalomethyl, C ⁇ -C4alkoxy, trihalomethoxy, C ⁇ -C4acyloxy, C ⁇ -C4alkylthio, C ⁇ -C 4 alkylsulfinyl, C ⁇ -C 4 alkylsulfonyl, hydroxy(C ⁇ -C )alkyl, -CO 2 H, -CN, -CONHR., -NH 2 , C ⁇ -C 4 alkylamino, di(C ⁇ -C 4 )alky
  • R is selected from H, OH or the C1-C12 esters or alkyl ethers thereof, benzyloxy, or halogen;
  • R 2 , R 3 , R 5 , and R 6 are independently selected from H, OH or the -C 12 esters or alkyl ethers thereof, halogen, cyano, Ci-C ⁇ alkyl, or trihalomethyl, preferably trifluoromethyl, with the proviso that, when Ri is H, R2 is not OH; R is selected from H, OH or the C1-C12 esters or alkyl ethers thereof, benzyloxy, halogen, cyano, Ci-C ⁇ alkyl, or trihalomethyl; X is selected from H, Ci-C ⁇ alkyl, cyano, nitro, trifluoromethyl, halogen; Y is the moiety
  • R 7 and R 8 are selected independently from H, C1-C6 alkyl, or combined by -(CH 2 )p-, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, -C4 alkylsulfinyl, -C4 alkylsulfonyl, hydroxy(C ⁇ -C 4 )alkyl, -CO 2 H, -CN, -CONH(C ⁇ -C 4 )alkyl, -NH 2 , C ⁇ -C 4 alkylamino, di-(C ⁇ -C4)alkylamino, -NHSO 2 (C ⁇ -C 4 )alkyl, -NHCO(C ⁇ -C )alkyl
  • the rings formed by a concatenated R7 and Rs, mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
  • substituted indole compounds of the present invention are those having the structural formulas I or II, above, wherein Ri is OH; R2 - Re are as defined above; X is selected from the group of CI, NO2, CN, CF3, or CH3; and Y is the moiety
  • R 8 and R7 and Rs are concatenated together as -(CH2)r.
  • r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, Ci-G-talkylthio, C ⁇ -C4alkylsulfinyl, C ⁇ -C4alkylsulfonyl, hydroxy (C ⁇ -C 4 )alkyl, -CO 2 H, -CN, -CONH(C ⁇ -C 4 )alkyl, -NH 2 , C ⁇ -C4alkylamino, di-(C ⁇ - C 4 )alkylamino, -NHSO 2 (C ⁇ -C 4 )alkyl, -NHCO(C ⁇ -C 4 )alkyl, and -NO 2 ; and the pharmaceutically acceptable salts
  • R7 and Rs are concatenated together as -(CH 2 )p-, wherein p is an integer of from 2 to 6, preferably 4 to 6, the ring so formed is optionally substituted with 1-3 substituents selected from a group containing C1-C 3 alkyl, trifluoromethyl, halogen, hydrogen, phenyl, nitro, -CN.
  • the invention includes sulfate, sulfamates and sulfate esters of phenolic groups of the substituted indoles. Sulfates can be readily prepared by the reaction of the free phenolic compounds with sulfur trioxide complexed with an amine such as pyridine, trimethylamine, triethylamine, etc.
  • Sulfamates can be prepared by treating the free phenolic compound with the desired amino or alkylamino or dialkylamino sulfamyl chloride in the presence of a suitable base such as pyridine.
  • Sulfate esters can be prepared by reaction of the free phenol with the desired alkanesulfonyl chloride in the presence of a suitable base such as pyridine.
  • this invention includes compounds containing phosphates at the phenol as well as dialkyl phosphates.
  • Phosphates can be prepared by reaction of the phenol with the appropriate chlorophosphate.
  • the dialkylphosphates can be hydrolyzed to yield the free phosphates.
  • Phosphinates are also claimed where the phenol is reacted with the desired dialkylphosphinic chloride to yield the desired dialkylphosphinate of the phenol.
  • the invention includes acceptable salt forms of the substituted indole formed from the addition reaction with either inorganic or organic acids.
  • Inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid useful as well as organic acids such as acetic acid, propionic acid, citric acid, maleic acid, malic acid, tartaric acid, phthalic acid, succinic acid, methanesulfonic acid, toluenesulfonic acid, napthalenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid are useful.
  • this invention includes quaternary ammonium salts of the compounds herein. These can be prepared by reacting the nucleophilic amines of the side chain with a suitably reactive alkylating agent such as an alkyl halide or benzyl halide.
  • the present invention includes methods for strengthening bone and for inhibiting, alleviating, preventing or treating bone disorders including Paget's disease, osteoporosis, including steroid-induced osteoporosis and post-menopausal osteoporosis, tumor-induced hypercalcemia and malignant osteolytic bone disease, bone degradation due to metastases from cancers, such as breast and prostate cancer, and bone destruction characteristic of multiple myeloma, disorders of bone remodeling, tumor induced hypercalcemia, and malignant osteolytic bone disease.
  • the administration of the regimens of this invention may also be used in methods for reducing the fracture risk and occurrence in a recipient.
  • These methods each comprise administering to a mammal in need thereof a bisphosphonate and a pharmaceutically effective amount of one of the substituted indoles taught herein and optionally a pharmaceutically effective amount of one or more estrogens. These administrations may be therapeutic or prophylactic.
  • substituted indole compounds for use in these methods are l-[4-(2- Azepan-lyl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-lH-indol-5-ol, also known as TSE-424, and 2-(4-Hydroxy-phenyl)-3-methyl-l-(4-(2-piperidin-l-yl- ethoxy)-benzyl]-lH-indol-5-ol, also known as ERA-923.
  • the present invention includes methods utilizing, in conjunction with a bisphosphonate compound and, optionally, an estrogen, a first subset or subgroup of substituted indole compounds of the formulas III or IN, below:
  • variable substituents including R, R 2 , R-, R 4 , R 5 , R 6 , n, X, and Y are as defined above, or a pharmaceutically acceptable salt thereof.
  • Rj is selected from H, OH or the C1-C12 esters or alkyl ethers thereof, benzyloxy, or halogen;
  • R 2 , R 3 , R 5 , and R 6 are independently selected from H, OH or the -C12 esters or alkyl ethers thereof, halogen, cyano, alkyl, or trihalomethyl, preferably trifluoromethyl, with the proviso that, when Ri is H, R2 is not OH;
  • R 4 is selected from H, OH or the -C1 2 esters or alkyl ethers thereof, benzyloxy, halogen, cyano, C ⁇ -C ⁇ alkyl, or trihalomethyl;
  • X is selected from H, Ci-C ⁇ alkyl, cyano, nitro, trifluoromethyl, halogen;
  • Y is the moiety
  • R 7 and R 8 are selected independently from H, Ci-Cg alkyl, or combined by -(CH 2 )p-, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C ⁇ -C4alkyl, trihalomethyl, C ⁇ -C4alkoxy, trihalomethoxy, C ⁇ - C4alkylthio, C ⁇ -C 4 alkylsulfinyl, C ⁇ -C4alkylsulfonyl, hydroxy(C ⁇ -C )alkyl, -CO 2 H, -CN, -CONH(C ⁇ -C 4 )alkyl, -NH 2 , C ⁇ -C 4 alkylamino, diC ⁇ -C 4 alkylamino, -NHSO 2 (C ⁇ -C 4 )alkyl, -NHCO(C ⁇ -C 4 )alky
  • the rings formed by a concatenated R7 and R$, mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
  • substituted indole compounds of this first subset of compounds are those having the structural formulas I or II, above, wherein Ri is OH; R2 - R ⁇ are as defined above; X is selected from the group of CI, NO2, CN, CF3, or CH3; and Y is the moiety
  • R 8 and R7 and R_ are concatenated together as -(CH2)r , wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C ⁇ -C4alkylthio, C ⁇ -C4alkylsulfinyl, C ⁇ -C4alkylsulfonyl, hydroxy(C ⁇ -C 4 )alkyl, -CO 2 H, -CN, -CONH(C ⁇ -C 4 )alkyl, -NH 2 , C ⁇ -C 4 alkylamino, di(C ⁇ -C 4 )alkylamino, -NHSO 2 (C ⁇ -C 4 )alkyl, -NHCO(C ⁇ -C4)alkyl and -NO 2 ; and the pharmaceutically acceptable salts thereof
  • this first subset of compounds when R7 and Rs are concatenated together as -(CH2)p-, wherein p is an integer of from 2 to 6, preferably 4 to 6, the ring so formed is optionally substituted with 1-3 substituents selected from a group containing -Chalky!, trifluoromethyl, halogen, hydrogen, phenyl, nitro, -CN.
  • substituents selected from a group containing -Chalky!, trifluoromethyl, halogen, hydrogen, phenyl, nitro, -CN.
  • Aryloxy-alkyl-dialkylamines or aryloxy-alkyl-cyclic amines useful as intermediates in the production of the compounds above can be produced and used as disclosed in WO 99/19293, published April 22, 1999, the subject matter of which is also incorporated herein by reference.
  • a second subset or subgroup of substituted indole compounds useful with this invention includes those of formulas (N) or (NI), below:
  • variable substituents including Rphenol R 2 , R 3 , R 4 , R 5 , R 6 , n, X, and Y are as defined above, or a pharmaceutically acceptable salt thereof.
  • a third subset of substituted indole compounds useful with the present invention include those of the formulae Nil and NDI:
  • n 1, 2 or 3 and the variable substituents including R réelle R 2 , R 3 , R 4 , R 5 , R 6 , n, X, and Y are as defined above, or a pharmaceutically acceptable salt thereof.
  • the compounds of this third subset or subgroup of substituted indole compounds can be produced by the methods described in U.S. Patent No. 5,880,137 (Miller et al.), which is incorporated herein by reference, or by other methods known in the art.
  • Ri is selected from H, OH or the C1-C12 esters or alkyl ethers thereof, halogen;
  • R 2 , R 3 , R , R 5 , and R 6 are independently selected from H, OH or the C1-C 2 esters or alkyl ethers thereof, halogen, cyano, Cj-C ⁇ alkyl, or trihalomethyl, preferably trifluoromethyl, with the proviso that, when Ri is H, R2 is not OH;
  • X is selected from H, C ⁇ -C alkyl, cyano, nitro, trifluoromethyl, halogen;
  • Y is the moiety
  • the rings formed by a concatenated R7 and R_, mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
  • substituted indole compounds of the present invention are those having the structural formulas I through VIII, above, wherein Ri is OH; R 2 - Re are as defined above; X is selected from the group of CI, NO2, CN, CF3, or CH3; and
  • Y is the moiety
  • R 8 and R7 and R_ are concatenated together as -(CH2) .
  • r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C ⁇ -C 4 )alkyl, -CO 2 H, -CN, -CONH(C ⁇ -C 4 )alkyl, -NH 2 , C1-C4 alkylamino, di(C ⁇ - C 4 )alkylamino, -NHSO 2 (C ⁇ -C 4 )alkyl, -NHCO(C ⁇ -C 4 )alkyl, and -NO 2 ; and the pharmaceutically acceptable salt
  • the invention includes sulfate, sulfamates and sulfate esters of phenolic groups.
  • Sulfates can be readily prepared by the reaction of the free phenolic compounds with sulfur trioxide complexed with an amine such as pyridine, trimethylamine, triethylamine, etc.
  • Sulfamates can be prepared by treating the free phenolic compound with the desired amino or alkylamino or dialkylamino sulfamyl chloride in the presence of a suitable base such as pyridine.
  • Sulfate esters can be prepared by reaction of the free phenol with the desired alkanesulfonyl chloride in the presence of a suitable base such as pyridine.
  • this invention includes compounds containing phosphates at the phenol as well as dialkyl phosphates.
  • Phosphates can be prepared by reaction of the phenol with the appropriate chlorophosphate.
  • the dialkylphosphates can be hydrolyzed to yield the free phosphates.
  • Phosphinates are also claimed where the phenol is reacted with the desired dialkylphosphinic chloride to yield the desired dialkylphosphinate of the phenol.
  • the invention includes acceptable salt forms formed from the addition reaction with either inorganic or organic acids.
  • Inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid useful as well as organic acids such as acetic acid, propionic acid, citric acid, maleic acid, malic acid, tartaric acid, phthalic acid, succinic acid, methanesulfonic acid, toluenesulfonic acid, napthalenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid are useful.
  • this invention includes quaternary ammonium salts of the compounds herein. These can be prepared by reacting the nucleophilic amines of the side chain with a suitably reactive alkylating agent such as an alkyl halide or benzyl halide.
  • estrogens useful in the formulations of this invention include estrone, estriol, equilin, estradiene, equilenin, ethinyl estradiol, 17 ⁇ -estradiol, 17 ⁇ -dihydroequilenin, 17 ⁇ -dihydroequilenin (U.S. Patent 2,834,712), 17 ⁇ -dihydroequilin, 17 ⁇ -dihydroequilin, menstranol and conjugated estrogenic hormones, such as those in Wyeth-Ayerst Laboratories' Premarin ® products (P.O. Box 8299, Philadelphia, PA 19101, U.S.A.).
  • Phytoestrogens such as equol or enterolactone, may also be used in the present formulations and methods.
  • a preferred embodiment of this invention comprises pharmaceutical compositions and methods of treatment utilizing conjugated estrogenic hormones, such as those in Wyeth-Ayerst Laboratories' Premarin ® products, with one or more compounds of Formulas (I) or (III) listed herein.
  • conjugated estrogenic hormones such as those in Wyeth-Ayerst Laboratories' Premarin ® products, with one or more compounds of Formulas (I) or (III) listed herein.
  • Esterified estrogens such as those sold by Solvay Pharmaceuticals, Inc. under the Estratab® tradename, may also be used with the present formulations.
  • the salts of the applicable estrogens most preferably the sodium salts.
  • Examples of these preferred salts are Sodium estrone sulfate, Sodium equilin sulfate, Sodium 17alpha-dihydroequilin sulfate, Sodium 17alpha-estradiol sulfate, Sodium Delta8,9- dehydroestrone sulfate, Sodium equilenin sulfate, Sodium 17beta-dihydroequilin sulfate, Sodium 17alpha- dihydroequilenin sulfate, Sodium 17beta-estradiol sulfate, Sodium 17beta- dihydroequilenin sulfate, Estrone 3-sodium sulfate, Equilin 3-sodium sulfate, 17alpha-Dihydroequilin 3-sodium sulfate, 3beta-Hydroxy-estra-5(10)J-dien-17-one 3-sodium sulf
  • a substituted indole compound selected from l-[4-(2- Azepan- lyl- ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-lH-indol-5-ol, also known as TSE- 424, and 2-(4-Hydroxy-phenyl)-3-methyl-l-(4-(2-piperidin-l-yl-ethoxy)-benzyl]-lH- indol-5-ol, also known as ERA-923, or a pharmaceutically acceptable salt of TSE-424 or ERA-923; and b) a bisphosphonate compound selected from the group of , Alendronate,
  • the dosage, regimen and mode of administration of these compounds will vary according to the extent of the malady and the individual being treated and will be subject to the judgement of the medical practitioner involved. It is preferred that the administration of one or more of the bisphosphonates and substituted indole compounds herein begin at a low dose and be increased until the desired effects are achieved.
  • Effective administration of these compounds may be given at an effective dose of from about 0.1 mg/day to about 500 mg/day. Preferably, administration will be from about 1 mg/day to about 200 mg/day in a single dose or in two or more divided doses.
  • Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, parenterally (including intravenous, intraperitoneal and subcutaneous injections), and transdermally.
  • transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
  • the active ingredient in the formulations and methods of this invention is l-[4-(2-Azepan-lyl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-lH-indol-5-ol, also known as TSE-424, or a pharmaceutically acceptable salt thereof
  • the preferred daily dosage for oral delivery is from about 0.1 to about 50 mg, preferably from about
  • the active ingredient in the formulations and methods of this invention is 2-(4-Hydroxy-phenyl)-3-methyl-l-(4-(2-piperidin-l-yl-ethoxy)-benzyl]-lH-indol- 5-ol, also known as ERA-923, or a pharmaceutically acceptable salt form thereof
  • the preferred daily dosage for oral delivery is from about 0.1 to about 200 mg, preferably from about 2.5 to about 100 mg per day.
  • Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions.
  • Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
  • Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, , xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar.
  • pharmaceutically acceptable diluents including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, micro
  • Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s).
  • Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin.
  • Water soluble suppository bases such as polyethylene glycols of various molecular weights, may also be used.
  • the pharmaceutically effective doses for the bisphosphonates and substituted indoles and the estrogens when used herein will be understood to be those sufficient to provide a desirable diminution in the risk or prevalence of the bone disease or disorder in question.
  • the compounds will be administered at a dose effective to maintain or increase bone mass density in the recipient, as directed by a medical professional.
  • the bisphosphonate compounds of these methods may be administered in regimens and at dosages known in the art.
  • alendronate sodium which is sold by Merck & Co., Inc. under the Fosamax ® name, has a recommended dosage of
  • Tiludronate sodium marketed by Sanofi Pharmaceuticals under the Skelid ® brandname, may be taken as a single 400 mg daily oral dose.
  • Etidronate sodium offered by MGI Pharma,
  • the estrogens herein may be administered according to the regimens and doses known in the art.
  • the preferred Premarin ® conjugated estrogen tablets may be administered as described in pages 3302-3305 of the Physicians' Desk Reference, 54 Edition, 2000, Medical Economics Company, Inc., Montvale, NJ 07645-1742.
  • estrogens useful with the present invention include OGEN ® (estropipate tablets), ESTRATAB ® (esterified estrogens tablets), ESTRACE ® estradiol vaginal cream, CLIMARA ® (estradiol transdermal system), ESTRADERM ® (transdermal system), MENESTTM (esterified estrogens tablets), ORTHO-EST ® (estropipate tablets), CENESTINTM (synthetic conjugated estrogens), ALORA ® (estradiol transdermal system), ESTINYL ® (ethynil estradiol), and the VIVELLE ® and VIVELLE-DOT ® (estradiol transdermal systems).
  • OGEN ® estropipate tablets
  • ESTRATAB ® estradiol vaginal cream
  • CLIMARA ® estradiol transdermal system
  • ESTRADERM ® transdermal system
  • MENESTTM esterified estrogens tablets
  • ORTHO-EST ® estropipat
  • Esterified estrogens 75-80% estrone sulfate Estratab 0.3, 0.625, 1.25, 2.5 mg
  • Estradiol Alora (twice weekly) 0.025, 0.0375, 0.05, 0.075,
  • Estradiol Fematrix 25 50, 75, 100 ⁇ g
  • Estradiol Ortho dienestrol cream 0.625 mg/g
  • Estrace vaginal cream 1.5 mg/g 1.0 mg g
  • the joint administration of two groups of compounds in these methods will be determined by a medical professional based upon the condition of the recipient and the malady for which the prophylaxis or treatment is provided. Administration of the two compounds may begin simultaneously or one may be introduced into an ongoing regimen of the other. For shorter term bisphosphonate administrations, such as the infusion of etidronate sodium, an initial regimen of the substituted indole compound may be preferred, which may continue through the term of bisphosphonate administration and beyond.
  • the joint administration of the three groups of compounds in the methods of this invention will likewise be determined by a medical professional based upon the condition of the recipient and the malady for which the prophylaxis or treatment is provided.
  • prophylaxis such as the combination of one of the substituted indoles herein and alendronate and one or more estrogens
  • administration of all compounds of the regimen may begin simultaneously or one may be introduced into an ongoing regimen of the other.
  • bisphosphonate administrations such as the infusion of etidronate sodium
  • an initial regimen of the substituted indole compound and one or more estrogens may be preferred, which may continue through the term of bisphosphonate administration and beyond.
  • the pharmaceutical compositions of the methods herein are supplied in unit dosage form, e.g. as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • the substituted indole compound(s) and bisphosphonate(s), and estrogens when utilised, of the present formulations may be administered in separate dosage units, such as separate pills, tablets, powders, etc., or combined into one formulation.
  • optimum dosages for the indole compounds and the bisphosphonates of these formulations have been determined, it may preferable to incorporate both into a single formulation for ease of administration.
  • the formulations herein may or may not include other pharmaceutically active components.
  • This invention also includes kits or packages of pharmaceutical formulations designed for use in the regimens and methods described herein.
  • kits are preferably designed for daily oral administration over the specified term or cycle of administration, preferably for the number of prescribed oral administrations per day, and organized so as to indicate a single oral formulation or combination of oral formulations to be taken on each day of the regimen or cycle.
  • each kit will include oral tablets to be taken on each the days specified, in some embodiments one oral tablet will contain each of the combined daily dosages indicated and in other embodiments the administrations of the separate compounds will be present in separate formulations or compositions. It is most preferable that the package or kit shall have a calendar or days-of-the-week designation directing the administration of the appropriate compositions on the appropriate day or time.
  • a package or kit of this invention will include individual oral dosage formulations for each of the components of the invention.
  • one daily dosage tablet of a bisphosphonate selected Alendronate, Risedronate, Tiludronate, Ibandronate, Etidronate, Clodronate, Minodronate, Pamidronate, Zoledronate, Incadronate, Olpadronate or Neridronate, or a pharmaceutically acceptable salt thereof and one orally administerable formulation for a substituted indole compound of this invention, preferably l-[4-(2-Azepan-lyl- ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-lH-indol-5-ol or 2-(4-Hydroxy- phenyl)-3-methyl-l-(4-(2-pi ⁇ eridin-l-yl-ethoxy)-benzyl]-lH-indol-5-ol or a pharmaceutically acceptable salt
  • kit or package comprises a one month supply of the components described herein, i.e. from 28 to 31 daily administration amounts of each component.
  • Solid oral formulations preferably in the form of a film coated tablet or capsule, useful for this invention include the active pharmacological agents disclosed herein in combination with carrier or excipient systems having the components: a) a filler and disintegrant component comprising from about 5% to about 82% by weight (wght) of the total formulation, preferably between about 30% and about 80% of the formulation, of which from about 4% to about 40% by weight of the total formulation comprises one or more pharmaceutically acceptable disintegrants; b) optionally, a wetting agent comprising from about 0.2 to about 5% of the composition (wght), such as selected from the group of sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, sugar esters of fatty acids and glycerides of fatty acids; c) a fill
  • fatty acid esters e.g. sodium stearyl fumarate
  • fatty acids e.g. stearic acid
  • fatty alcohols e.g. glyceryl behenate, mineral oil, parrafins, hydrogenated vegetable oils, leucine, polyethylene glycols, metallic lauryl sulfates and sodium chloride; and d) optionally, a glidant comprising from about 0.1% to about 10% (wght) of the composition, the glidant selected from those known in the art, including from the group of silicon dioxide, talc, metallic stearates, calcium silicate, or metallic lauryl sulfates.
  • compositions described herein may be used in an uncoated or non- encapsulated solid form, preferably the final compositions are coated or encapsulated.
  • the pharmacological compositions may be optionally coated with a film coating, preferably comprising from about 0.3% to about 8% by weight of the overall composition.
  • Film coatings useful with the present formulations are known in the art and generally consist of a polymer (usually a cellulosic type of polymer), a colorant and a plasticizer. Additional ingredients such as wetting agents, sugars, flavors, oils and lubricants may be included in film coating formulations to impart certain characteristics to the film coat.
  • the compositions and formulations herein may also be combined and processed as a solid, then placed in a capsule form, such as a gelatin capsule.
  • the filler component listed above may utilize the filler or binder components known in the art for solid oral formulations.
  • Pharmaceutically acceptable fillers or binding agents selected from those known in the art including, but not limited to, lactose, microcrystalline cellulose, sucrose, mannitol, calcium phosphate, calcium carbonate, powdered cellulose, maltodextrin, sorbitol, starch, or xylitol.
  • veegum or xanthan gum cellulose floe
  • ion exchange resins or effervescent systems, such as those utilizing food acids (such as citric acid, tartaric acid, malic acid, fumaric acid, lactic acid, adipic acid, ascorbic acid, aspartic acid, erythorbic acid, glutamic acid, and succinic acid) and an alkaline carbonate component (such as sodium bicarbonate, calcium carbonate, magnesium carbonate, potassium carbonate, ammonium carbonate, etc.).
  • the disintegrant(s) useful herein will comprise from about 4% to about 40% of the composition by weight, preferably from about 15% to about 35%, more preferably from about 20% to about 35%.
  • Some components may have multiple functions in the formulations of this invention, acting e.g. as both a filler and a disintegrant, such a component may be referred to as a filler disintegrant and its function in a specific formulation may be singular even though its properties may allow multiple functionality.
  • formulations of this invention are pharmaceutical formulations containing a pharmaceutically effective amount of an active pharmacological agent and a carrier or excipient system comprising: a) a filler and disintegrant component comprising between about 50% and about 87% of the formulation, with from about 4% to about 40% of the formulation comprising one or more disintegrant agents; b) a wetting agent comprising between about 0.5% and about 2.7% of the formulation; c) a lubricant comprising between about 0.2% and about 5.5% of the formulation; and d) a glidant comprising between about 0.1% and about 5.5% of the formulation.
  • the percentages listed in the formulations above indicate percentages by weight of the total weight of the components listed from a) to d).
  • the formulations above also preferably contain an optional antioxidant component, preferably ascorbic acid, at a concentration of from about 0.5% to about 5.5% by weight of the formulation.
  • the formulations are also preferably contained within a pharmaceutically acceptable capsule, such as a gel capsule, or coated with a film coating comprising from about 0.3% to about 8% by weight of the formulation.
  • This invention also comprises a pharmaceutical carrier or excipient systems useful in pharmaceutical compositions utilizing as an active ingredient one or more of the compounds described herein, or a pharmaceutically acceptable salt thereof, as described herein.
  • These pharmaceutical carrier or excipient systems comprise, by weight: a) a filler and disintegrant component comprising between about 54% and about 80% of the formulation, with the disintegrant agent(s) therein comprising from about 4% to about 40% by weight of the overall formulation; b) a wetting agent comprising between about 0.55% and about 2.5% of the formulation; c) a lubricant comprising between about 0.2% and about 5.5% of the formulation; and d) a glidant comprising between about 0.1% and about 5.0% of the formulation.
  • the more preferred carrier or excipient systems above also optionally and preferably contain an antioxidant component, preferably ascorbic acid, at a concentration of from about 0.1% to about 5.0% by weight.
  • this invention further provides a product comprising a compound of formula I or II as defined above or a pharmaceutically acceptable salt thereof and a bisphosphonate or a pharmaceutically acceptable salt thereof, and optionally one or more estrogens, or a pharmaceutically acceptable salt thereof for administration as a combined preparation for simultaneous, separate or sequential use in treatment of bone disorders in a mammal.
  • This invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I or II as defined above or a pharmaceutically acceptable salt thereof, and a bisphosphonate or a pharmaceutically acceptable salt thereof and optionally one or more estrogens, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • Example 1. TSE-424 Acetate -Rapid Dissolution Formulations
  • Wet granulation of the formulations as described in Table 1 may be carried out by mixing the drug and ascorbic acid with a portion of the lactose, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate.
  • the sodium lauryl sulfate is dissolved in the water and used to granulate the mixture of powders in a high shear mixer.
  • the granulation is dried in a fluid bed dryer to a moisture of 2-3%.
  • the particle size of the dried granulation is controlled by passing through a mill equipped with knife-edged blades and using a 20- or 30-mesh screen.
  • the silicon dioxide and remaining lactose, microcrystalline cellulose, pregelatinized starch, and sodium starch glycolate are mixed with the milled granulation in a tumble- type mixer.
  • the final blend is prepared by adding magnesium stearate to the tumble- type mixer and mixing. Compression is carried out on a rotary tablet press using appropriate size tooling. Coating is performed in conventional coating pans and applying the coating suspension to achieve a suitable film coat.
  • a Amount in formula is adjusted for actual potency of TSE-424 as free base. Corresponding adjustment made with Lactose. b Used in process but does not appear in the final product.
  • ERA-923 tablets are compressed to a tablet weight of up to 640 mg to achieve the target dose (up to 100 mg). Tablets may then be film coated.
  • a preferred carrier or excipient system for formulating a granulation of from about 2 to about 8% by weight of one of the active pharmacological agents of this invention, preferably about 5%, may be produced utilizing the carrier or excipient components on a weight percentage; lactose from about 32% to about 38%, microcrystalline cellulose from about 32% to about 38%, pregelatinized starch from about 12% to about 16%, ascorbic acid from about 1% to about 2%, sodium lauryl sulfate from about 1% to about 2%, sodium starch glycolate from about 4% to about 8%, silicon dioxide from about 0.1% to about 0.2% and magnesium stearate from about 0.3% to about 0.7%.
  • a formulation of this invention utilizing TSE-424 as the active ingredient at a 5% granulation was prepared utilizing the components listed below in a granulation part of components and a dry part.
  • TSE-424 tablet weight mg mg of film coat applied/tablet

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP01952365A 2000-07-06 2001-06-29 Kombinationen aus bisphosphonaten, östrogenmitteln und gegebenenfalls östrogenen Withdrawn EP1299093A2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21606900P 2000-07-06 2000-07-06
US21618800P 2000-07-06 2000-07-06
US216069P 2000-07-06
US216188P 2000-07-06
PCT/US2001/020970 WO2002003976A2 (en) 2000-07-06 2001-06-29 Combinations of bisphosphonates, estrogenic agents and optionally estrogens

Publications (1)

Publication Number Publication Date
EP1299093A2 true EP1299093A2 (de) 2003-04-09

Family

ID=26910620

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01952365A Withdrawn EP1299093A2 (de) 2000-07-06 2001-06-29 Kombinationen aus bisphosphonaten, östrogenmitteln und gegebenenfalls östrogenen

Country Status (8)

Country Link
EP (1) EP1299093A2 (de)
JP (1) JP2004502730A (de)
CN (1) CN1450913A (de)
AU (1) AU2001273125A1 (de)
BR (1) BR0112364A (de)
CA (1) CA2415052A1 (de)
MX (1) MXPA02012897A (de)
WO (1) WO2002003976A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271781A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
BR0313182A (pt) 2002-07-24 2007-07-24 Childrens Hosp Medical Center composições e produtos contendo equol enantiomérico
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
SI1596870T2 (sl) 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
NZ743651A (en) 2015-12-09 2023-07-28 Univ Illinois Benzothiophene-based selective estrogen receptor downregulators
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EA201990187A1 (ru) 2016-07-01 2019-07-31 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP4455146A3 (de) 2017-06-29 2025-01-01 G1 Therapeutics, Inc. Morphische formen von git38 und verfahren zur herstellung davon
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
MX2022007659A (es) 2019-12-20 2022-07-19 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
CN117940133A (zh) 2021-06-08 2024-04-26 C4医药公司 用于突变braf的降解的治疗剂
EP4565585A1 (de) 2022-08-03 2025-06-11 Bristol-Myers Squibb Company Verbindungen zur modulation des ret-proteins
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
JP2025540907A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000778B1 (en) * 1998-05-15 2004-10-31 Wyeth Corp 2-phenyl-1-/4-(2-aminoethoxy)-benzyl/-indole in combination with estrogens
EP1080073A1 (de) * 1998-05-15 2001-03-07 American Home Products Corporation Zusammensetzungen aus 2-phenyl-indol verbindungen und östrogen formulierungen
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0203976A2 *

Also Published As

Publication number Publication date
WO2002003976A3 (en) 2003-01-03
JP2004502730A (ja) 2004-01-29
BR0112364A (pt) 2003-07-29
CN1450913A (zh) 2003-10-22
AU2001273125A1 (en) 2002-01-21
CA2415052A1 (en) 2002-01-17
MXPA02012897A (es) 2003-10-24
WO2002003976A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
WO2002003976A2 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003992A2 (en) Use of substituted indole compounds for treating prosthesis-related bone degeneration
EP1359940A2 (de) Kombinationen aus statinen, östrogenmitteln und gegebenenfalls östrogenen
US20020028805A1 (en) Methods of inhibiting uterotrophic effects of estrogenic agents
US6358991B2 (en) Methods of treating neuropeptide Y-related conditions
WO2002003987A2 (en) Pharmaceutical compositions of estrogenic agents
AU2001271741A1 (en) Pharmaceutical compositions of estrogenic agents
EP1311293A2 (de) Kombinationen aus ssri und östrogenmitteln
US6509332B2 (en) Methods of treating excessive intraocular pressure
WO2002003989A2 (en) Use of substituted indole compounds for treating sphincter incontinence
US20020016318A1 (en) Methods of treating breast disorders
CA2414111A1 (en) Use of substituted indole compounds for increasing nitric oxide synthase activity
US6455568B2 (en) Combination therapy for inhibiting sphincter incontinence
US6369051B1 (en) Combinations of SSRI and estrogenic agents
US20020028792A1 (en) Combinations of bisphosphonates, estrogens and estrogenic agents
US20020019373A1 (en) Combinations of bisphosphonates and estrogenic agents
US20020025952A1 (en) Combinations of statins, estrogens and estrogenic agents
US20020028800A1 (en) Combination therapy for prosthesis-related bone degeneration
US6465454B2 (en) Combinations of statins and estrogenic agents
EP1656938A1 (de) Kombinationen aus SSRI und Oestrogenmitteln
US20020022613A1 (en) Methods of treating prosthesis-related bone degeneration
HK1089695A (en) Combinations of ssri and estrogenic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030106

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050101